Does This U.S. FDA Letter Spell Trouble For Biocon?

Biocon Ltd.’s plan to launch its key diabetes drug in one of the biggest markets for most Indian drugmakers may be delayed after the company failed to receive an approval from the U.S. regulator.Th...